By: Elana Gotkine From: healthday.com For patients with intermediate-risk breast cancer, chest wall irradiation (CWI) after mastectomy does not influence 10-year overall survival, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio. Ian Kunkler, M.B., B.Chir., from the University of Edinburgh in the United Kingdom, and colleagues …
Study finds depression can reduce survival among women with breast cancer
By: Carlos Andres López, New Mexico State University From: medicalxpress.com New research from New Mexico State University shows depression can reduce survival rates among American women diagnosed with breast cancer. Jagdish Khubchandani, a professor of public health sciences at NMSU, led a study to understand the long-term impacts of depression among American women with breast cancer. Khubchandani’s study partners included the Kirk Kerkorian …
High breast density tied to impaired recurrence-free cancer survival
By: Amerigo Allegretto From: auntminnie.com Recurrence-free breast cancer survival is less likely in women with high breast density compared to women with low density, according to research published April 18 in The Breast. A team led by Kristina Lång, MD, PhD, from Lund University in Sweden found that these results were especially evident for women with screening-detected cancers. However, they found …
Don’t Rule Out Breast Cancer Surgery for 90-Year-Olds
By: Ed Susman From: medpagetoday.com Primary breast cancer surgery for nonagenarians in good physical shape was associated with improved survival compared with a non-surgical approach, retrospective data from a single center in Italy showed. Among 123 breast cancer patients ages 90 and above, median overall survival from the time of diagnosis reached 54 months for those who underwent mastectomy or …
New treatment approach improves recurrence-free survival in early breast cancer patients
Source: University of California – Los Angeles Health Sciences From: news-medical.net A new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a new study co-led by UCLA Health Jonsson Comprehensive Cancer Center …
Mammography data are ‘practice-changing’ in US for older women with breast cancer
By: Matthew Shinkle From: healio.com Key takeaways: Researchers noted similar efficacy results between study arms for breast cancer-specific survival and OS. Study findings found less frequent mammograms to yield similar outcomes as annual mammograms. SAN ANTONIO — Women aged 50 years or older who de-escalated to less-frequent mammography 3 years after curative surgery for early-stage breast cancer had similar outcomes …
No Added Benefit From Chemo in This Breast Cancer Subtype
By: Liam Davenport From: medscape.com TOPLINE: Women with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive lobular carcinoma who are treated with endocrine therapy do not derive any additional survival benefit from neoadjuvant or adjuvant chemotherapy. METHODOLOGY: Studies evaluating the long-term effects of chemotherapy in patients with invasive lobular carcinoma are limited and often “show inconclusive results,” …
Clinical Challenges: Beyond CDK4/6 Inhibition in Advanced HR-Positive Breast Cancer
By: Charles Bankhead From: medpagetoday.com The emergence of CDK4/6 inhibitors has reshaped the therapeutic landscape for advanced hormone receptor (HR)-positive breast cancer, extending progression-free survival (PFS) and in some cases overall survival (OS) when combined with first-line endocrine therapy. Unfortunately, most patients eventually progress, and the next step after CDK4/6 inhibition is perhaps “the hottest topic that all of us …
Fox Chase Researchers Present Findings on BRCA-Mutated Breast Cancer at American Society for Radiation Oncology Meeting
From: foxchase.org The presence of BRCA1 and BRCA2 mutations in breast cancer patients did not predict improved survival for patients who received radiation therapy, according to findings presented by Fox Chase Cancer Center researchers recently at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Diego. “BRCA1 and BRCA2 are two genes that play an important role in …
Musashi 1 in breast cancer: Implications for dormancy and survival in bone marrow
By: Impact Journals LLC From: medicalxpress.com A new research paper titled “Increased expression of musashi 1 on breast cancer cells has implication to understand dormancy and survival in bone marrow” has been published in Aging. Breast cancer (BC) stem cells (CSCs) resist treatment and can exist as dormant cells in tissues such as the bone marrow (BM). Years before clinical …
- Page 1 of 2
- 1
- 2